TCT 2023 Late-Breaking Science Collection

Published: 09 January 2024

  • Views:

    Views Icon 250
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations. 

Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data. 

About the episode

TCT 23 - We are joined by Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, SA) for an insightful summary of the late-breaking trials that are expected to have an impact on interventional science and clinical practice.


Trials covered in detail include:

Agent IDE


Recorded remotely from Jeddah, 2023.

Editor: Jordan Rance
Video Specialist: Dan Brent

Faculty Biographies

Mirvat Alasnag

Mirvat Alasnag

Director of Catheterization Laboratory

Dr Mirvat Alasnag is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3), joining the board in October 2020 and is also on the editorial board for US Cardiology Review (USC).

Dr Mirvat Alasnag is the Director of the Catheterization Laboratory at the King Fahd Armed Forces Hospital in Jeddah, Saudi Arabia. She was the first female interventional cardiologist in the Gulf region and has since represented women on multiple medical committees, including the Saudi Arabian Cardiac Interventional Society Board & the EAPCI Women’s Steering Committee. She is the current ACCWIC International Working Group Chair and an SCAI WIN member.

Dr Alasnag trained in Clinical Cardiology and Interventional Cardiology at Loma Linda University Medical Center (Loma Linda, California) and Harper University Hospital, Detroit Medical Center (Detroit, Michigan), respectively. Since her graduation in 2009 to date,…

View full profile


You must be to comment. If you are not registered, you can register here.